medigraphic.com
ISSN 1995-9427 (Print)

2020, Number 1

<< Back Next >>

Invest Medicoquir 2020; 12 (1)

Latent Tuberculosis Infection. Diagnosis and Treatment in Closed Settings

Calzado BA, Oliva NN, Vergara ÁR

Language: Spanish
References: 38
Page:
PDF size: 158.31 Kb.


ABSTRACT

Globally the Tuberculosis remains a disease cause. In closed settings like is a health problem. The diagnosis and treatment of Latent Tuberculosis Infection on high-risk groups, is one of the main priority for the strategy to eliminate Tuberculosis in low burden countries like Cuba. It is not only avoiding the Tuberculosis reactivation, also the contagious to susceptible groups in places with favorable conditions to the spread like closed settings. The goal of Control Tuberculosis National Program from Cuba is to achieve the elimination of this disease, that means to reach one case per 100 000 populations per year. Two high-risk groups affected the program indicators: Human Immunodeficiency Virus co-infection and closed settings, when don’t get the needed results of Tuberculosis control, cause required special priory attention. This article updates the diagnosis and treatment recommendations for Latent Tuberculosis Infection, as well the importance of his detections in closed settings.


REFERENCES

  1. World Health Organization. Global Tuberculosis Report 2016. Geneva: WHO; 2016.

  2. World Health Organization. Global strategy and targets for tuberculosis prevention, care and control after 2015. Geneva: WHO; 2015.

  3. González OE, De Armas L, Baly A, Gálvez AM, Álvarez M, Gustavo F, et al. Impacto económico-social del PNCTB en la población cubana. Cad.Saúde Pública. Rio de Janeiro. 2000;16(23):697-699.

  4. World Health Organization. Global tuberculosis control: surveillance, planning, financing: WHO Report 2005. Geneva: WHO; 2005.

  5. Coker R et al. Risk factors for pulmonary tuberculosis in Russia: case-control study. BMJ 2006; 332:85–87.

  6. World Health Organization. The global Plan to Stop TB 2011–2015. Geneva: WHO; 2010.

  7. González OE, De Armas L. Tuberculosis, procedimientos para su vigilancia y control: experiencia cubana, La Habana; 2010.

  8. Tiemersma EW et al. Natural history of tuberculosis: duration and fatality of untreated pulmonary tuberculosis in HIV negative patients: A systematic review. PLoS ONE, 2011, 6(4): e17601.

  9. Ministerio de Salud Pública. Programa Nacional y Normas de Procedimientos para la prevención y del control de la Tuberculosis. 4 ta ed. La Habana: MINSAP; 2014.

  10. Horsburgh C R Jr, Rubin E J. Latent Tuberculosis Infection in the United States. N.Engl.J.Med. 2011;364(15):1441-8.

  11. Organización Mundial de la Salud. Directrices sobre la atención de la infección tuberculosa latente: The End TB Strategy. Ginebra: OMS; 2015.

  12. Porta M. A Dictionary of Epidemiology.5 th ed. United States of America: Oxford University Press, Inc.;2008.

  13. Cain KP, Varma JK. You have to find TB to treat TB. Int J Tuberc Lung Dis 2011;15(7):854.

  14. OPS/OMS. Situación de la tuberculosis en las Américas,2016 [internet]. 2017 [citado 22 de mayo de 2017]. Disponible en: http://www.paho.org/tuberculosis.

  15. Dirección de Registros Médicos y Estadísticas de Salud del Ministerio de Salud Pública. Anuario Estadístico de Salud 2016. La Habana: MINSAP; 2017.

  16. Lobacheva T, Asikainen T, Giesecke J. Risk factors for developing tuberculosis in remand prisons in St. Petersburg, Russia: a case-control study. European Journal of Epidemiology 2007;22( 2):121-127.

  17. Coninx R, Eshaya-Chauvin B, Reyes H. Tuberculosis in prisons. Lancet 1995;346:1238-1239.

  18. MacIntyre CR, Kendig N, Kummer L, Birago S, Graham NM. Impact of tuberculosis control measures and crowding on the incidence of tuberculous infection in Maryland prisons. Clin.Infect.Dis. 1997;24:1060-1067.

  19. Hammet TM, Gaiter JL, Crawford C. Reaching seriously at-risk populations: health interventions in criminal justice settings. HealthEduc.Behav. 1998;25:99-120.

  20. Coninx R, Maher D, Reyes H, Grzemska M. Tuberculosis in prisons in countries with high prevalence. BMJ 2000;320:440-442.

  21. S. Carbonara, S. Babudieri, B. Longo, G. Starnini, R. Monarca, B. Brunetti, M. Andreoni, G. Pastore, V. De Marco, G. Rezza. Correlates of Mycobacterium tuberculosis infection in a prison population. ERJ 2005;25(6):1070-1076.

  22. MacNeil JR et al. An Unanswered Health Disparity: Tuberculosis Among Correctional Inmates, 1993 Through 2003. American Journal of Public Health 2005;95(10):1800-1805.

  23. Organización Mundial de la Salud. El control de la tuberculosis en prisiones: manual para directores de programa. Ginebra: OMS; 2000.

  24. Reyes H. Pitfalls of TB management in prisons, revisited. Int.J.PrisonHealth. 2007; 3:43-67.

  25. Organización Panamericana de la Salud. Guía para el control de la tuberculosis en poblaciones privadas de libertad de América Latina y el Caribe. Washington, D.C.: OPS, 2008.

  26. Duarte B, López S, Gallardo G, Cabrera O, Pérez JM. Evaluación del Programa de Tuberculosis en Instituciones Cerradas. Rev.CienciasMédicas. 2015;19(2):253-265.

  27. Mor Z, Adler A, Leventhal A, Volovic I, Rosenfeld E, Lobato MN, Chemtob D. Tuberculosis behind bars in Israel: policy making within a dynamic situation. Isr.Med.Assoc.J. 2008;10(3):202-206.

  28. Diuana V et al. Health in the prison system: representations and practices by prison guards in Rio de Janeiro, Brazil. Cad. Saúde Pública, Rio de Janeiro. 2008;24(8):1887-1896.

  29. Crofton J. Tuberculosis Clínica. New York: Macmillan Education LTD; 1994.

  30. Matarama M. Medicina Interna, Diagnóstico y Tratamiento. La Habana: Editorial Ciencias Médicas. 2005.

  31. Álvarez R. Temas de Medicina General Integral. Vol. II. La Habana: Editorial Ciencias Médicas. 2008.

  32. Fauci A, Longo F. Harrison's Principles of internal medicine. 17th ed. United States of America: The McGraw-Hill Companies, Inc; 2008.

  33. Saunders C. Cecil Medicin. 23rd ed. United States of America: Elsevier, Inc: 2007.

  34. Rivas-Santiago B, Vieyra-Reyes P, Araujo A. Cell immunity response in human pulmonary tuberculosis. Review.Invest.Clin. 2005;46(4):391-412.

  35. Heldal E, Docker H, Caugant DA, Tverdal A. Pulmonary tuberculosis in Norwegian patients. The role of reactivation, re-infection and primary infection assessed by previous mass screening data and restrictionfragment length polymorphism analysis. Int.J.Tuberc.Lung. Dis. 2000;4(4):300–307.

  36. Shea KM, Kammerer JS, Winston CA, Navin TR, Horsburgh CR. Estimated rate of reactivation of latent tuberculosis infection in the United States, overall and by population subgroup. Am.J.Epidemiol. 2014;179(2):216–225.

  37. Mack U, Migliori GB, Sester M, Rieder HL, Ehlers S, Goletti D, et al and TBNET. LTBI: latent tuberculosis infection or lasting immune responses to M. tuberculosis? A TBNET consensus statement. Eur. Respir. J. 2009;33:956-73.

  38. World Health Organization. Global Tuberculosis Report. 2015. Geneva: WHO; 2015.




2020     |     www.medigraphic.com